Chemistry and Structural Biology
IMB’s Chemistry and Structural Biology Division conducts pure, strategic and applied research in organic and medicinal chemistry, structural biology, biochemistry, pharmacology, virology, bacteriology, and biotechnology.
IMB scientists discover, design and synthesise new compounds, investigate the molecular and structural basis of physiology and disease, and invent new treatments to improve health.
Researchers within the division have expertise throughout the drug discovery pipeline and work together with academic and industry partners around the world to make important contributions towards understanding and treating a range of human diseases and conditions. These include: cancer; chronic pain; inflammatory, cardiovascular and neurodegenerative diseases; obesity and type 2 diabetes; and bacterial, viral and parasitic infections. Our researchers are also working to develop more effective agricultural products and more efficient clean energy production systems.
During 2013, the division supported research in the following areas:
- chemistry and human therapeutics
- protein structure in drug and insecticide design
- bio-inspired design of solar fuel systems
- molecular biodiscovery: learning from nature
- drugs and diagnostics for superbugs, viruses and cancer
- antibiotic discovery, understanding insulin signalling and protein structure
- design and discovery of bioactive peptides and proteins in venomous animals
- pharmacology of marine toxins
- combinatorial chemistry and molecular design.
The division uses advanced technologies in NMR spectroscopy; protein crystallography; computational design; chemical synthesis; protein and cell activation and signalling; tissue analysis; and rodent pharmacology.
|Professor David Fairlie||Division Head||Chemistry and human therapeutics||inflammatory disease; viral infections; cancers; Alzheimer's disease; cardiovascular diseases; type 2 diabetes; obesity|
|Professor David Craik||Group Leader||Protein structure in drug and insecticide design||cancer; chronic pain; multiple sclerosis; cardiovascular disease; drug discovery; drug development; cyclic peptides; cyclotides; agriculture|
|Professor Ben Hankamer||Group Leader||Bio-inspired design of solar fuel systems||biofuels; biohydrogen; biodiesel; algae; bioreactors; biotechnology|
|Professor Rob Capon||Group Leader||Molecular biodiscovery: learning from nature||Alzheimer's disease; Parkinson's disease; cancer; infectious disease; malaria; tuberculosis; bacterial/fungal/parasitic infections; pain; obesity|
|Professor Matt Cooper||Group Leader||Drugs and diagnostics for superbugs, viruses and cancer||superbugs; antibiotics; viral/bacterial infections; tuberculosis; dengue fever; inflammation; drug discovery; drug development; cancer|
|Professor Jenny Martin||Group Leader||Antibiotic discovery, understanding insulin signalling, protein structure and drug design||bacterial infection; inflammation; diabetes; drug discovery; superbugs; antibacterials; antibiotics; protein crystallography|
|Professor Paul Alewood||Group Leader||Design and discovery of bioactive peptides and proteins in venomous animals||chronic pain; irritable bowel syndrome; breast cancer; inflammation; congestive heart failure; insecticides; drug discovery; drug development|
|Professor Richard Lewis||Group Leader||Pharmacology of marine toxins||chronic pain; peptides; drug discovery; drug development|
|Professor Glenn King||Group Leader||Bugs and drugs||chronic pain; stroke; biotechnology; insect venom; insecticides; agriculture|
|Associate Professor Mark Smythe||Group Leader||Combinatorial chemistry and molecular design||asthma; leukaemia; inflammatory bowel disease; peptides; drug discovery; drug development|
|Dr Irina Vetter||Group Leader||Understanding pain pathways||chronic pain; toxins; ion channels; neuropathy; cancer; diabetes; irritable bowel syndrome; drug discovery; drug development|